首页> 美国卫生研究院文献>BMC Urology >Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer

【2h】

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer

机译：对局部前列腺癌进行最大程度雄激素阻断的雄激素剥夺治疗的持续时间

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundPrimary androgen deprivation therapy (ADT) is a treatment option not only for advanced but also for localized prostate cancer. However, the appropriate duration for primary ADT for localized prostate cancer has not been defined and few studies have addressed this issue. In this study, we aimed to determine the appropriate duration of ADT for localized prostate cancer.

机译：背景技术雄激素剥夺治疗（ADT）不仅是晚期患者的治疗选择，还是局部前列腺癌的治疗选择。但是，对于局限性前列腺癌原发性ADT的合适持续时间尚未确定，很少有研究解决此问题。在这项研究中，我们旨在确定局限性前列腺癌的ADT持续时间。

著录项

期刊名称 BMC Urology
作者
Naohiro Fujimoto; Tatsuhiko Kubo; Hideo Shinsaka; Masahiro Matsumoto; Shohei Shimajiri; Tetsuro Matsumoto;
展开▼
作者单位

展开▼
年(卷),期 2011(11),-1
年度 2011
页码 7
总页数 6
原文格式 PDF
正文语种
中图分类泌尿科学（泌尿生殖系疾病）;小儿泌尿科学;肾疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer [J] . Naohiro Fujimoto, Tatsuhiko Kubo, Hideo Shinsaka, BMC Urology . 2011,第1期

机译：对局部前列腺癌进行最大程度雄激素阻断的雄激素剥夺治疗的持续时间
2. Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu. [J] . Takizawa I, Nishiyama T, Hara N, The Prostate . 2010,第13期

机译：血清前列腺特异性抗原水平反映了接受雄激素剥夺治疗的局部前列腺癌患者的雄激素环境：肿瘤恶性潜能和雄激素环境。
3. Re: Liselotte MS Boeve, Maarten CCM Hulshof, Andre N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019; 75: 410-8 Future Steps for Definitive Therapy in Metastatic Prostate Cancer: Lessons from the HORRAD Trial [J] . Shinde Ashwin, Li Richard, Amini Arya, European urology . 2019,第3期

机译：Re：Liselotte Ms Boeve，Maarten CCM Hulshof，Andre N. Vis等人。与雄激素剥夺治疗相比，对雄激素剥夺治疗的生存对雄激素剥夺治疗与前瞻性随机临床试验中原发性骨转移前列腺癌前列腺患者的同时剥夺治疗的影响：来自血腥审判的数据。 EUR UROL 2019; 75：410-8转移性前列腺癌中的明确治疗的未来步骤：来自血轮试验的教训
4. Serum levels of sex hormones before and after androgen deprivation therapy in Japanese prostate cancer patients [C] . A. Komiya, K. Ichimatsu, A. Morii, International Congress of Andrology . 2009

机译：日本前列腺癌患者中雄激素剥夺治疗前后的性激素血清水平
5. Duration of androgen deprivation therapy and nadir of testosterone at 20 ng/dL predict testosterone recovery to supracastrate level in prostate cancer patients who received external beam radiotherapy [D] . TAKEI, Akinori 2019

机译：雄激素剥夺治疗的持续时间和最低20 ng / dL的睾丸激素最低值可预测接受外照射的前列腺癌患者的睾丸激素恢复至超水平
6. Clinical outcomes of anti-androgen withdrawal and subsequent alternative anti-androgen therapy for advanced prostate cancer following failure of initial maximum androgen blockade [O] . HIROYUKI MOMOZONO, HIDEAKI MIYAKE, HIROMOTO TEI, -1

机译：最初最大雄激素阻滞失败后抗雄激素撤药和后续替代抗雄激素疗法治疗晚期前列腺癌的临床结果
7. Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer [O] . Naohiro Fujimoto, Tatsuhiko Kubo, Hideo Shinsaka, 2011

机译：对局部前列腺癌进行最大程度雄激素阻断的雄激素剥夺治疗的持续时间

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer

摘要

著录项

相似文献

相关主题

期刊订阅